Secondary acute myeloblastic leukaemia (AML) (expressing 11q23 mutation) occurring 11 months after chemotherapy/radiotherapy for paediatric non-Hodgkin lymphoma (NHL).

The occurrence of 11q23 cytogenetic abnormalities in drug-induced acute myeloid leukaemia (AML) is now well recognized. They are most frequently associated with topoisomerase II inhibitor administration. We here describe the case history of a 15-year-old child who presented with Stage III B-cell non-Hodgkin's lymphoma (NHL) and was treated with anthracyclines, alkylating agents and low-dose mediastinal radiotherapy.

Lipoperoxides as an index of free radical activity in bone marrow transplant recipients. Preliminary observations.

It has been previously demonstrated that the conditioning therapy given to bone marrow transplant (BMT) recipients creates a high oxidant stress, resulting in a measured reduction in antioxidants, such as glutathione peroxidase (GSH-Px), vitamin E, and cell peroxide fragilities. As part of a current intervention trial of antioxidant therapy in BMT recipients, plasma thiobarbituric acid reactive substances (TBARS) were measured to assess peroxidation and free radical activity. Measurements were performed before and after conditioning therapy, and then at weekly intervals for a period of 6 wk after transplantation in 20 patients (10 controls and 10 antioxidant therapy [AOT] recipients).

3 cases of destructive facial granulocytic sarcoma in childhood - acute myeloid-leukemia expressing lymphoid associated antigens.

Three children, two from the Middle East and one from Greece, presented to this clinic for treatment of malignant facial tumours destroying bone. In each case biopsy histology led to an initial diagnosis of 'lymphoma'. Further characterisation of the tumour cells by cytochemistry and immunophenotyping established diagnoses of acute myeloid leukaemia, with myeloblasts in all three cases expressing lymphoid associated cell surface antigens.